Abstract
Fabry disease (FD) is an X-linked inborn metabolic disorder due to partial or complete lysosomal α-galactosidase A deficiency. FD is characterized by progressive renal insufficiency and cardio- and cerebrovascular involvement. Restricted access on Gb3-independent tissue injury experimental models has limited the understanding of FD pathophysiology and delayed the development of new therapies. Accumulating glycosphingolipids, mainly Gb3 and lysoGb3, are Fabry specific markers used in clinical follow up. However, recent studies suggest there is a need for additional markers to monitor FD clinical course or response to treatment. We used a gla-knockout zebrafish (ZF) to investigate alternative biomarkers in Gb3-free-conditions. RNA sequencing was used to identify transcriptomic signatures in kidney tissues discriminating gla-mutant (M) from wild type (WT) ZF. Gene Ontology (GO) and KEGG pathways analysis showed upregulation of immune system activation and downregulation of oxidative phosphorylation pathways in kidneys from M ZF. In addition, upregulation of the Ca2+ signaling pathway was also detectable in M ZF kidneys. Importantly, disruption of mitochondrial and lysosome-related pathways observed in M ZF was validated by immunohistochemistry. Thus, this ZF model expands the pathophysiological understanding of FD, the Gb3-independent effects of gla mutations could be used to explore new therapeutic targets for FD.
Funder
Western Norway Health Region
European Union’s Horizon 2020 research and innovation programme
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference86 articles.
1. Fabry disease;Germain;Orphanet. J. Rare Dis.,2010
2. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria;Tondel;Am. J. Kidney Dis.,2008
3. Uncertain diagnosis of Fabry disease: Consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance;Smid;Int. J. Cardiol.,2014
4. Carnicer-Caceres, C., Arranz-Amo, J.A., Cea-Arestin, C., Camprodon-Gomez, M., Moreno-Martinez, D., Lucas-Del-Pozo, S., Molto-Abad, M., Tigri-Santina, A., Agraz-Pamplona, I., and Rodriguez-Palomares, J.F. (2021). Biomarkers in Fabry Disease. Implications for clinical diagnosis and follow-up. J. Clin. Med., 10.
5. Diagnosis and management of cardiovascular involvement in fabry disease;Rubino;Heart Fail Clin.,2022
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献